

Status: Currently Official on 16-Feb-2025  
Official Date: Official as of 01-Aug-2017  
Document Type: USP Monographs  
DocId: GUID-569291B4-AE82-42AD-8933-F963EB6002BB\_1\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M78765\\_01\\_01](https://doi.org/10.31003/USPNF_M78765_01_01)  
DOI Ref: slg98

© 2025 USPC  
Do not distribute

# Sulfacetamide Sodium and Prednisolone Acetate Ophthalmic Ointment

## DEFINITION

Sulfacetamide Sodium and Prednisolone Acetate Ophthalmic Ointment is a sterile ointment containing NLT 90.0% and NMT 110.0% of the labeled amounts of sulfacetamide sodium ( $C_8H_9N_2NaO_3S \cdot H_2O$ ) and prednisolone acetate ( $C_{23}H_{30}O_6$ ).

## IDENTIFICATION

- **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the tests for *Sulfacetamide Sodium* and *Prednisolone Acetate* in the Assay.
- **B.** The UV absorption spectra of the major peak of the *Sample solution* and that of the *Standard solution* exhibit maxima and minima at the same wavelengths, as obtained in the tests for *Sulfacetamide Sodium* and *Prednisolone Acetate* in the Assay.

## ASSAY

### • SULFACETAMIDE SODIUM

**Diluent:** Dilute [methanol](#) (1 in 5)

**Mobile phase:** [Methanol](#), [glacial acetic acid](#), and [water](#) (100:10:890), filtered and degassed

**Standard solution:** Transfer about 50 mg of [USP Sulfacetamide Sodium RS](#) to a 40-mL centrifuge tube. Add 10.0 mL of *Diluent*, insert the stopper in the tube, and mix using a vortex mixer for about 3 min to dissolve. Add 7.5 mL of [heptane](#), insert the stopper in the tube, and mix using a vortex mixer for another 3 min. Centrifuge to effect separation of the phases. Withdraw and discard the upper heptane layer. Transfer 3.0 mL of the bottom layer to a 500-mL volumetric flask, add *Diluent* to volume, and mix.

**System suitability solution:** Dissolve 3 mg of [sulfanilamide](#) in 100 mL of the *Standard solution*, and mix.

**Sample solution:** Transfer a quantity of Ophthalmic Ointment nominally equivalent to about 100 mg of sulfacetamide sodium to a 40-mL centrifuge tube. Add 15.0 mL of [heptane](#), insert the stopper in the tube, and mix using a vortex mixer for about 3 min to dissolve the Ophthalmic Ointment. Add 20.0 mL of *Diluent*, insert the stopper in the tube, and mix using a vortex mixer for 3 min. Centrifuge to effect separation of the phases. Withdraw and discard the upper heptane layer. Transfer 3.0 mL of the bottom layer to a 500-mL volumetric flask, dilute with *Diluent* to volume, and mix.

### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** 254-nm diode array

**Column:** 4.6-mm × 25-cm; packing [L1](#)

**Flow rate:** 1.5 mL/min

**Injection volume:** 90 µL

### System suitability

**Samples:** *Standard solution* and *System suitability solution*

#### Suitability requirements

**Resolution:** NLT 3 between the sulfacetamide and sulfanilamide peaks, *System suitability solution*

**Column efficiency:** NLT 1500 theoretical plates, *Standard solution*

**Relative standard deviation:** NMT 2.0%, *Standard solution*

### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of sulfacetamide sodium ( $C_8H_9N_2NaO_3S \cdot H_2O$ ) in the portion of Ophthalmic Ointment taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

$r_U$  = peak response of sulfacetamide sodium from the *Sample solution*

$r_S$  = peak response of sulfacetamide sodium from the *Standard solution*

$C_S$  = concentration of [USP Sulfacetamide Sodium RS](#), calculated on the anhydrous basis, in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of sulfacetamide sodium in the *Sample solution* (mg/mL)

$M_{r1}$  = molecular weight of sulfacetamide sodium monohydrate, 254.24

$M_{r2}$  = molecular weight of anhydrous sulfacetamide sodium, 236.23

**Acceptance criteria:** 90.0%–110.0%

• **PREDNISOLONE ACETATE**

**Diluent:** Dilute [methanol](#) (9 in 10)

**Mobile phase:** [Acetonitrile](#) and [water](#) (400:600), filtered and degassed

**Internal standard solution:** 0.7 mg/mL of norethindrone in *Diluent*

**Standard stock solution:** 0.8 mg/mL of [USP Prednisolone Acetate RS](#) in *Diluent*

**Standard solution:** 0.04 mg/mL of [USP Prednisolone Acetate RS](#) prepared as follows. Transfer 5.0 mL of *Standard stock solution* to a 100-mL volumetric flask, add 5.0 mL of *Internal standard solution*, dilute with *Diluent* to volume, and mix.

**Sample solution:** Transfer a quantity of Ophthalmic Ointment nominally equivalent to about 4 mg of prednisolone acetate to a 50-mL centrifuge tube. Add 10.0 mL of [heptane](#), and mix using a vortex mixer for about 2 min to dissolve the Ophthalmic Ointment. Add 5.0 mL of *Internal standard solution* and 20.0 mL of *Diluent*, and mix using a vortex mixer for 2 min. Centrifuge to effect separation of the phases. Withdraw and discard the upper heptane layer. Transfer the lower layer to a 100-mL volumetric flask. Add *Diluent* to volume, and mix.

**Chromatographic system**

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** 254-nm diode array

**Column:** 3.9-mm × 30-cm; packing [L1](#)

**Flow rate:** 1.5 mL/min

**Injection volume:** 40 µL

**System suitability**

**Sample:** *Standard solution*

[NOTE—The relative retention times for prednisolone acetate and norethindrone are about 1.0 and 1.5, respectively.]

**Suitability requirements**

**Resolution:** NLT 4.5 between the prednisolone and norethindrone peaks

**Column efficiency:** NLT 3000 theoretical plates for the prednisolone peak

**Tailing factor:** NMT 2.5 for the prednisolone peak

**Relative standard deviation:** NMT 1.5% for the peak response ratio of prednisolone acetate to norethindrone

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of prednisolone acetate ( $C_{23}H_{30}O_6$ ) in the portion of Ophthalmic Ointment taken:

$$\text{Result} = (R_U/R_S) \times (C_S/C_U) \times 100$$

$R_U$  = peak response ratio of prednisolone acetate to the internal standard peak from the *Sample solution*

$R_S$  = peak response ratio of prednisolone acetate to the internal standard peak from the *Standard solution*

$C_S$  = concentration of [USP Prednisolone Acetate RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of prednisolone acetate in the *Sample solution* (mg/mL)

**Acceptance criteria:** 90.0%–110.0%

**SPECIFIC TESTS**

• **STERILITY TESTS (71):** Meets the requirements

• **OTHER REQUIREMENTS:** It meets the requirements for *Particulate and Foreign Matter* and *Container Contents* in [Ophthalmic Products—Quality Tests \(771\)](#), [Drug Product Quality, Universal Tests, Particulate and Foreign Matter](#) and [Container Contents](#).

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in collapsible ophthalmic ointment tubes that are tamper-proof so that sterility is assured at time of first use.
- **USP REFERENCE STANDARDS** (11).
  - [USP Prednisolone Acetate RS](#)
  - [USP Sulfacetamide Sodium RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
SULFACETAMIDE SODIUM AND PREDNISOLONE ACETATE OPHTHALMIC OINTMENT	<a href="#">Documentary Standards Support</a>	SM22020 Small Molecules 2
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM22020 Small Molecules 2

**Chromatographic Database Information:** [Chromatographic Database](#)

#### Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 39(5)

**Current DocID:** GUID-569291B4-AE82-42AD-8933-F963EB6002BB\_1\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M78765\\_01\\_01](https://doi.org/10.31003/USPNF_M78765_01_01)

**DOI ref:** [slg98](#)

OFFICIAL